Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Brain Cancer treatment details. Biologic therapy. National Cancer Institute, National Institutes of Health, Bethesda, MD, United States

Survival: 4.3 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: United States
City/State/Province: Bethesda, MD
Hospital: National Cancer Institute, National Institutes of Health
Journal: Link
Date: 1/2013

This phase 2 study involved recurrent glioblastoma patients who were divided into two separate patient groups. Group A consisted of 32 patients with a median age of 57 years who were not previously treated with bevacizumab; 72% were male. Group B consisted of 31 patients with a median age of 54 years who were previously treated with but resistant to bevacizumab; 68% were male.

Patients in groups A and B were treated with the biologic therapy agent sunitinib, which is a small molecule inhibitor of VEGF receptors and interferes with cancer cell growth.

Toxicity information was not separated based on patient group because both groups received the same drug and dose. There was one treatment-related death due to pneumonia in this study. Bleeding, neutropenia, and lymphopenia were also reported.

The median overall survival for groups A and B was 9.4 and 4.37 months, respectively.

Correspondence: Dr. Nguyen Kreisl; email:

E-mail to a Friend Email Physician More Information